Ranbaxy Laboratories’ arm receives approval to market RAN Donepezil in Canada

08 Jan 2014 Evaluate

Ranbaxy Laboratories' wholly owned subsidiary Ranbaxy Pharmaceuticals Canada Inc. (RPCI), has received an approval on December 24, 2013 to manufacture and market RAN-Donepezil Hydrochloride 5 mg and 10 mg tablets from Health Canada.

The total market size of Aricept (Donepezil Hydrochloride) in Canada is $153.9 million and growing at 38% (extended units). Donepezil Hydrochloride is indicated in the treatment of dementia in Alzheimer’s patients.

Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories, India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×